The aims of the USC Norris Cancer Control Research Program are to elucidate the etiology of cancer risk behaviors in the general population and develop primary prevention interventions that modify cancer risk behavior and enhance secondary prevention, clinical care, and survivorship.
These aims serve the overarching goal of reducing and eliminating cancer health disparities among the populations represented in the USC Norris catchment area, with implications for other populations globally. The Program's goals align with the USC Norris strategic plan by: a) developing and testing new interventions that impact the cancer burden; b) applying cutting-edge technology and methodology to assess exposures and disseminate interventions; and c) spanning the continuum of care from primary prevention to survivorship. A hallmark of this Program has been the application of innovative theory and methodology to develop integrated lines of research on cancer risk behaviors and preventive interventions. Given that the diverse, vulnerable, and disadvantaged members of the catchment area reached by the Program's work also reflect the disparities seen at the US population level and the Program makes significant strides in addressing the mission of NCI's efforts in cancer control and population sciences. Recent achievements of the Program, which is led by two internationally-recognized experts, Mary Ann Pentz (primary prevention) and Anna Wu (secondary prevention and survivorship), include 1) understanding mental health comorbidities with tobacco use to inform more tailored smoking cessation programs for vulnerable smokers who have been unable to quit by other means; 2) promoting cultural values and decreasing perceived cultural discrimination as means to improve tobacco prevention and control efforts with Hispanic youth and adults; and 3) utilizing executive function and mindfulness skills training in primary prevention programs that target diet, physical inactivity, and other cancer risk behaviors in youth and applying such interventions to cancer patients, caregivers, and families to improve treatment outcomes. The 30 members represent five schools and 13 departments at USC, and have $15M in peer-reviewed funding (direct costs), 33% of which is from NCI, 27% from other NIH sources, and 33% from other peer-reviewed funding sources. The Program is highly productive with 756 publications of which 17% are inter-programmatic, 23% intra-programmatic and 53% inter-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-45
Application #
9838180
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244

Showing the most recent 10 out of 842 publications